HENDERSON MICHAEL THOMAS 4
4 · Apogee Therapeutics, Inc. · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Apogee (APGE) CEO Michael Henderson Sells Shares
What Happened
Michael T. Henderson, CEO of Apogee Therapeutics (APGE), sold a total of 20,000 shares in open‑market transactions on February 11, 2026 for aggregate proceeds of approximately $1,266,952. The sales were reported as three tranches: 11,494 shares at a weighted average $62.96 ($723,662), 7,551 shares at a weighted average $63.73 ($481,225), and 955 shares at a weighted average $64.99 ($62,065). These were sales (not purchases); sales can be routine and do not necessarily signal a change in view of the company.
Key Details
- Transaction date: February 11, 2026 (Form 4 filed February 13, 2026). Filing appears timely.
- Trades and reported weighted averages:
- 11,494 shares @ $62.96 = $723,662 (prices ranged $62.33–$63.32) [F2]
- 7,551 shares @ $63.73 = $481,225 (prices ranged $63.33–$64.32) [F3]
- 955 shares @ $64.99 = $62,065 (prices ranged $64.95–$65.50) [F4]
- Total shares sold: 20,000; total proceeds ≈ $1,266,952 (~$1.27M).
- Shares owned after transaction: not provided in the materials you supplied (check the Form 4 for the post-transaction beneficial ownership number).
- Notable footnotes: Sales were executed pursuant to a Rule 10b5‑1 trading plan adopted August 13, 2025 [F1]. The reported prices are weighted averages; detailed per-price breakdowns are available on request as noted in F2–F4.
Context
A Rule 10b5‑1 plan allows insiders to sell pre‑scheduled amounts at predetermined times and is commonly used to avoid trading based on material nonpublic information. Weighted average prices and ranges indicate the shares were sold in multiple executions during the trading day; the filer has pledged to provide detailed per-price breakdowns if requested.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-11$62.96/sh−11,494$723,662→ 1,181,493 total - Sale
Common Stock
[F1][F3]2026-02-11$63.73/sh−7,551$481,225→ 1,173,942 total - Sale
Common Stock
[F1][F4]2026-02-11$64.99/sh−955$62,065→ 1,172,987 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.33 to $63.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.33 to $64.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.95 to $65.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.